Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 448

Results For "Inc"

7104 News Found

Ami Organics Q2 FY23 revenue up 20.2%; Profit up 9%
News | November 08, 2022

Ami Organics Q2 FY23 revenue up 20.2%; Profit up 9%

The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23


Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr
News | November 08, 2022

Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr

The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.


SeQuent Scientific to acquire 100% stake in Tineta Pharma
News | November 08, 2022

SeQuent Scientific to acquire 100% stake in Tineta Pharma

The acquisition is for an enterprise value of Rs. 218 crores


Astec LifeSciences plan Capex of Rs. 300 - 350 Cr
News | November 08, 2022

Astec LifeSciences plan Capex of Rs. 300 - 350 Cr

R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab


Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%
News | November 07, 2022

Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%

Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%


Lupin receives tentative approval from USFDA for Drospirenone Tablets
Drug Approval | November 07, 2022

Lupin receives tentative approval from USFDA for Drospirenone Tablets

Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US


EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression
Clinical Trials | November 07, 2022

EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression

Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems


GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr
News | November 04, 2022

GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr

The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022